Montelukast Reduces Serum Levels of Eosinophil-Derived Neurotoxin in Preschool Asthma.

ABSTRACT:

Purpose

Several markers for eosinophilic inflammation have been proposed to predict response to asthma treatment. However, definitive criteria for treatment decisions have not yet been established. We investigate a potentially useful relatively non-invasive biomarker, eosinophil-derived neurotoxin (EDN), to predict favorable responses to budesonide or montelukast, common treatment for children with asthma.

Methods

Young children (1 to 6 years old) were enrolled in this randomized, parallel, 2-group, open-label trial. Criteria for eligibility included: 1) being symptomatic during the run-in period; and 2) having a serum EDN (sEDN) level ≥ 53 ng/mL, with positive specific immunoglobulin E to house dust mite. Eligible patients were randomly placed into 2 groups: the BIS group r

SUBMITTER: Kim CK 

PROVIDER: S-EPMC6182197 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature